In vivo, once weekly administration of PRT2527 (30 mg/kg) potently inhibited tumor growth in a H1703 (PBRM1-protein-deficient lung cancer) CDX model (39% TGI) (Figure 4E). Here, PBRM1 is linked to neoplasm.